A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America

Noopur Raje\textsuperscript{a}, Garson David Roodman\textsuperscript{b}, Wolfgang Willenbacher\textsuperscript{c}, Kazuyuki Shimizu\textsuperscript{d}, Ramón García-Sanz\textsuperscript{e}, Evangelos Terpos\textsuperscript{f}, Lisa Kennedy\textsuperscript{g}, Lorenzo Sabatelli\textsuperscript{h}, Michele Intorcia\textsuperscript{i}, Gyu Hechmati\textsuperscript{j}

\textsuperscript{a} Massachusetts General Hospital Cancer Center, Boston, Massachusetts USA
\textsuperscript{b} Indiana University Simon Cancer Center, Indianapolis, Indiana USA
\textsuperscript{c} Innsbruck University Hospital Internal Medicine V: Hematology & Oncology & OncoTyrol – Center of Personalized Cancer Medicine, Innsbruck, Austria
\textsuperscript{d} Department of Hematology/Oncology, National Hospital Organization Higashi Nagoya National Hospital, Nagoya, Japan
\textsuperscript{e} Hospital Universitario de Salamanca, Salamanca, Spain
\textsuperscript{f} University of Athens School of Medicine, Alexandra General Hospital, Athens, Greece
\textsuperscript{g} Epiphany, Los Angeles, California USA
\textsuperscript{h} Amgen (Europe) GmbH, Zug, Switzerland
\textsuperscript{i} Global Health Economics, Amgen Inc, Thousand Oaks, California USA

Correspondence: Michele Intorcia, Amgen GmbH Europe, Dammstrasse 23, 6300 Zug, Switzerland, email: intorcia@amgen.com

Transparency Statement

Declaration of funding
This study was funded by Amgen, Inc.

Declaration of financial/other relationships
NR has consulted for Amgen, Inc., BMS, Celgene, Merck, Novartis, Roche, and Takeda and received research funding from AstraZeneca. GDR has consulted for Amgen Inc. WW has participated in Steering Committees for Amgen; is an employee for Oncotyrol (20%); has participated in Advisory Boards and has consulted for Amgen, BMS, Celgene, ct, Gilead, Janssen, Novartis, Merck, Mundipharma, Pfizer, Roche, Sandoz, Takeda, and The Binding Site; has presented lectures for Amgen, Abbvie, BMS, Celgene, Gilead, Janssen, Mundipharma, Myelom- und Lymphomsebsthilfe Österreich, Novartis, Roche, Sandoz, Takeda, and The Binding Site; has participated in speaker bureau for Gilead; and has received research funding from Amgen, BMS, Celgene, Janssen, Novartis, Roche, Takeda, Oncotyrol, European Commission (FP7 - OPTATIO) and Bundesland Tirol Programm: ‘Translational research’. KS has consulted for Daiichi-Sankyo and Fujimoto Pharma; received research grants from Daiichi-Sankyo and honoraria from Daiichi-Sankyo and Fujimoto Pharma; and provided expert testimony for Amgen, Inc. RGS has received honoraria from Janssen, Takeda, and Pharmacyclics; received travel and accommodation expenses from Janssen, Takeda, and Celgene; and received research funding from Hospira. ET reports grants, personal fees, and non-financial support from Amgen, Celgene, and Janssen-Cilag; personal fees and non-financial support from Takeda; and personal fees from Novartis, GSK, Roche, and BMS, outside the submitted work. LK is a consultant for Amgen. LS, MI, and GH are employees of Amgen and hold Amgen stock. Peer reviewers on this manuscript have received an honorarium from JME for their review work. One reviewer discloses previous work on cost-effectiveness analyses sponsored by Novartis (maker of zoledronic acid) in which zoledronic acid was compared to denosumab; the results of these analyses have been reported in JME and elsewhere. This reviewer has not participated in work regarding
denosumab or zoledronic acid or sponsored by Novartis since 2013. The remaining peer reviewers have no relevant financial relationships to disclose.

**Author contributions**
NR, MI, and LS conceived and designed the study. LS constructed the model and performed data analysis. All authors interpreted data from the model. MI wrote the manuscript and all authors critically revised the manuscript. All authors provided their approval for publication of the final version and agree to be accountable for all aspects of the work.

**Acknowledgments**
The authors would like to thank Jacqui Buchanan, Sumita Bhatta, Daniela Niepel, Nicolas Despiegel, and Aurelien Jamotte for their useful insights during the development of this manuscript. Medical writing support, funded by Amgen, Inc., was provided by Kelly Soady (PhD) from Oxford PharmaGenesis, Oxford, UK.
Abstract

Objective: A large, pivotal, phase 3 trial in patients with newly diagnosed multiple myeloma (MM) demonstrated that denosumab, compared with zoledronic acid, was non-inferior for the prevention of skeletal-related events (SREs), extended the observed median progression-free survival (PFS) by 10.7 months, and showed significantly less renal toxicity. The cost-effectiveness of denosumab versus zoledronic acid in MM in the United States of America was assessed from societal and payer perspectives.

Methods: The XGEVA® Global Economic Model was developed by integrating data from the phase 3 trial comparing the efficacy of denosumab with zoledronic acid for the prevention of SREs in MM. SRE rates were adjusted to reflect the real-world incidence. The model included utility decrements for SREs, administration, serious adverse events (SAEs), and disease progression. Drug, administration, SRE management, SAEs, and anti-MM treatment costs were based on data from published studies. For the societal perspective, the model additionally included SRE-related direct non-medical costs and indirect costs. The net monetary benefit (NMB) was calculated using a willingness to pay threshold of US$150,000. One-way deterministic and probabilistic sensitivity analyses were conducted.

Results: From a societal perspective, compared with zoledronic acid, the use of denosumab resulted in an incremental cost of US$26,329 and an incremental quality-adjusted life-year (QALY) of 0.2439, translating into a cost per QALY gained of US$107,939 and a NMB of US$10,259 in favor of denosumab. Results were sensitive to SRE rates and PFS parameters.

Limitations: Costs were estimated from multiple sources, which varied by tumor type, patient population, country, and other parameters. PFS and overall survival were extrapolated beyond the follow-up of the primary analysis using fitted parametric curves.

Conclusion: Denosumab’s efficacy in delaying or preventing SREs, potential to improve PFS, and lack of renal toxicity makes it a cost-effective option for the prevention of SREs in MM compared with zoledronic acid.

Keywords: Cost-effectiveness; Denosumab, Zoledronic acid; Skeletal-related events; Multiple myeloma
Introduction

Multiple myeloma (MM) is a rare, incurable and aggressive cancer of plasma cell origin that accounts for 1.8% of all cancers in the United States of America (USA) and is the second most common hematological malignancy\(^1,2\). It is characterized by a chronic pattern of remission and relapse and features increased osteoclast activation, resulting from an imbalance between receptor activator of nuclear factor kappa B ligand (RANKL) and osteoprotegerin\(^1,3\). As a consequence of this disturbed equilibrium, approximately 80–90% of patients with MM develop osteolytic bone lesions, or soft spots that appear as ‘holes’ on a standard bone X-ray during the course of the disease\(^4,5\). These lesions never heal spontaneously, weaken the bone, increase the risk of fractures, and are the primary cause of bone pain in patients with MM\(^4,5\). During the course of the disease nearly all patients with MM are at risk of a broad range of bone complications, known as skeletal-related events (SREs)\(^2,6\). These include: (1) pathologic fractures; (2) spinal cord compression; (3) surgery to bone; and (4) radiation to bone\(^7\). SREs are associated with a substantial decrease in the patients’ health-related quality of life, largely due to bone pain and forced immobility, as well as poor prognosis and increased risk of death associated with MM\(^7,9\).

SREs are burdensome, not only for the patient, but also to the healthcare system. They lead to incrementally higher costs and healthcare resource use including significantly more hospitalizations, outpatient clinic visits and emergency department (ED) visits for patients with MM who have SREs versus those who do not\(^10,11\). Furthermore, healthcare resource use also increases with SRE burden\(^10,11\). A retrospective analysis found that, overall, all-cause total costs were approximately $80,000 (2016 US$) per patient per year (PPPY) higher for those with SREs than those without, and approximately $50,000 PPPY higher for those with multiple versus single SREs\(^10\).

The prevention or reduction of bone complications is considered a major goal of supportive care for patients with MM\(^12\). International guidelines recommend initiating therapy to prevent SREs along with antimaloma therapy for patients with active disease, even if osteolytic bone lesions are not apparent\(^13,14\). Until recently, treatment options for the prevention of SREs in MM in the USA were limited to bisphosphonates, with zoledronic acid being the standard of care (4 mg intravenously [IV] every 3–4 weeks). Despite the predominance of zoledronic acid in this setting, it is not without limitations including safety warnings for renal toxicity\(^15\), risk of acute-phase reactions\(^16,17\) and requiring intravenous administration\(^15\), all of which contribute to the healthcare resource burden in these patients\(^18\).

Denosumab was recently approved in the USA for the prevention of SREs in patients with MM\(^19\). It is a fully human monoclonal antibody of the immunoglobulin G2 isotype that binds to and neutralizes RANKL, thereby inhibiting osteoclast activation and function\(^19\). In contrast to zoledronic acid, denosumab is not excreted via the kidneys and, consequently, can be used regardless of the patients’ renal function, with no renal monitoring or dose adjustments required\(^15,19\). RANKL inhibition with denosumab is a novel approach to prevent SREs in patients with MM, as it exerts both potent antiresorptive activity and may have additional antitumor effects\(^20\). Denosumab is administered every 4 weeks (Q4W) as a subcutaneous injection (SC)\(^19\). Denosumab was approved in the USA and Europe for the prevention of SREs in patients with solid tumors in 2010; real-world data indicate that denosumab and zoledronic acid are the main agents used to prevent SREs in patients with solid tumors\(^19,21,22\).

The safety and efficacy of denosumab, compared with zoledronic acid, for the prevention of SREs in patients with MM was recently evaluated in the 20090482 study (NCT01345019), one of the largest clinical trials in MM to date. In this phase 3, double-blind, multicenter study, 1718 patients with newly diagnosed MM were randomized 1:1 to receive denosumab (120 mg, SC, Q4W) or zoledronic acid (4 mg, intravenously [adjusted], Q4W)\(^20\). The study met its primary endpoint; denosumab was
non-inferior to zoledronic acid in delaying time to first on-study SRE (hazard ratio [HR] = 0.98; 95% confidence interval [CI] = 0.85–1.14; p = 0.01). Owing to a high number of SREs (60%) during the first 3 months of the study, a post hoc landmark analysis at 15 months was performed for time to first SRE. This showed that, compared with zoledronic acid, denosumab demonstrated better efficacy in delaying time to first SRE (HR = 0.66; 95% CI = 0.44–0.98; p = 0.039)\(^\text{20}\). Median progression-free survival (PFS), assessed as an exploratory endpoint, was 46.1 months with denosumab versus 35.4 months with zoledronic acid (HR = 0.82; 95% CI = 0.68–0.99; descriptive p = 0.036), leading to an observed 10.7 month difference in median PFS between the two treatments\(^\text{20}\). Adverse events (AEs) in this phase 3 study reflected the known safety profile of each agent and were similar between treatment arms\(^\text{20}\).

Integrated analysis of the data from three identically designed, randomized, double-blind, phase 3 trials of patients with bone metastases and breast cancer, prostate cancer, other solid tumors or MM demonstrated that denosumab was superior to zoledronic acid in delaying the time to first SRE\(^\text{23}\), yet comparisons of the cost-effectiveness of denosumab and zoledronic acid have yielded variable conclusions\(^\text{24–30}\). This variability may have been caused by different perspectives of value. There is no single answer to the question of the value of an innovative drug. Traditionally, cost-effectiveness analyses have focused on direct medical costs, such as drug acquisition costs, and their short-term budget impact\(^\text{31}\). More recently, additional factors such as the comprehensive clinical, humanistic and downstream economic benefits of drugs have been incorporated into economic models in order to provide a societal perspective on drug value\(^\text{31}\). In the current analysis, which aimed to assess the value of denosumab for the prevention of SREs in patients with MM, we have taken into account this societal perspective, which places the patient at the center of the analysis. We have also provided an analysis from the payer perspective.

Given that denosumab has been shown to prevent or delay SREs, may extend PFS compared with zoledronic acid, and does not impact on renal function\(^\text{19}\), it was important to assess its economic value in patients with MM in the USA. The objective of the analysis was to estimate the incremental cost-effectiveness ratio (ICER) and the net monetary benefit (NMB) of denosumab versus zoledronic acid in patients with MM, from the perspectives of both society and payers.

**Methods**

The XGEVA\(^\text{®}\) Global Economic Model (X-GEM) used for this analysis builds on the model published in Stopeck et al., 2012 that evaluated the cost-effectiveness of denosumab versus zoledronic acid for the prevention of SREs in patients with solid tumors in the USA\(^\text{28}\). The model incorporates outcomes of the 20090482 study\(^\text{20}\).

**Model design**

A partitioned survival model was constructed to assess the cost-effectiveness of denosumab versus zoledronic acid in patients with newly diagnosed MM by integrating the treatment and outcomes of a cohort of patients who are at risk of experiencing SREs. The model structure was the same for both treatment arms.

Five health states were included, according to whether patients were on or off treatment with zoledronic acid or denosumab, had MM progression or not, or had died (Figure 1). Patients could transfer among health states every 4 weeks. The total time horizon was set to the patient’s remaining lifetime to capture all of the future health and economic outcomes expected from the alternatives compared\(^\text{32}\).

Four types of SRE can occur – radiation to bone, surgery to bone, spinal cord compression and pathologic fracture – and each is associated with a different mean cost and impact on patient quality
of life. To account for this, the model calculated the cost of a SRE based on the proportion of each type of SRE that occurred during the phase 3 study (Amgen data on file, 2017) (Table 1) and the cost of each SRE.

Model population
Patients newly diagnosed with MM and with at least one osteolytic lesion were included in the model. In order to reflect real-world practice, 10% of the model population was not able to receive zoledronic acid owing to pre-existing severe renal impairment; the model assumed that these patients would be treated with denosumab.

Model parameters
Clinical input was obtained from the 20090482 study and included the SRE rates, the SRE distribution, treatment compliance rates, treatment discontinuation rates, PFS and overall survival (OS) rates and serious adverse event (SAE) rates. Treatment discontinuation rates, PFS and mortality rates were derived from probability curves fitted to trial data and extrapolated beyond the follow-up of the primary analysis. The follow-up for the primary analysis was up to 45 months; the median time on study was similar between the two arms (17.3 months for denosumab vs 17.6 months for zoledronic acid). Additionally, a real-world adjustment for SRE rates was applied to the clinical trial results. The rates of SREs, SAEs, PFS, OS and treatment discontinuation were modeled independently of each other.

Skeletal-related event rates
To calculate the trial-based annual SRE rate, using data from the 20090482 study, the number of SREs experienced by patients in each arm was divided by the number of patient-years in the respective arm (Table 2).

Consistent with other published cost-effectiveness analyses in this therapeutic area, the model used constant rates for all SREs, the values of which depended on: (1) the specific treatment the patient was receiving to prevent SREs; and (2) whether the patient was on or off treatment for the prevention of SREs. Alternative SRE rate values, based on the results of a landmark analysis at 15 months, were also used. In this case, patients in each arm experienced differential rates before and 15 months after the start of SRE preventive treatment (Table 3).

The SRE rate for patients receiving no treatment (0.99 SRE/year) was estimated by dividing the SRE rate in the zoledronic acid arm by the rate ratio of SREs in patients with MM who were treated with zoledronic acid and patients with MM who did not receive treatment to prevent SREs; the rate ratio was taken from a managed care database study from the USA.

Skeletal-related event real-world adjustment
Real-world studies have found that the SRE rate for zoledronic acid was higher than those reported from clinical trials. To account for this difference, a real-world adjustment relative rate ratio of 2.84 was applied to the clinical trial results (i.e. the trial SRE rates were multiplied by the rate ratio). Although a real-world SRE adjustment factor lower than 2.84 has previously been reported for SREs in solid tumors, the adoption of 2.84 in the base case for this analysis is consistent with the available (albeit limited) evidence of SRE rates in MM.

Distribution of skeletal-related events
The model considered the SRE distribution as observed in the 20090482 study (Amgen data on file, 2017) without any further adjustment, as a proxy of real-world distribution of SREs (Table 1).
**Treatment compliance rates**

Treatment compliance was defined as the number of doses of zoledronic acid/denosumab received divided by the number of scheduled doses up to the end of investigational product administration for each patient. These data were derived from the 20090482 study\(^\text{20}\). The treatment compliance rate was 0.881 for denosumab and 0.854 for zoledronic acid.

**Treatment discontinuation rates**

Treatment discontinuation rates in the 20090482 study were similar between the denosumab and zoledronic acid arms\(^\text{20}\). The discontinuation of zoledronic acid and of denosumab was incorporated into the model based on treatment-specific data from the clinical trial with long-term extrapolation based on parametric fitting of the pooled individual data from the trial arms\(^\text{20}\). Treatment discontinuation rates were derived from the time-to-treatment-discontinuation probability distribution. Independent parametric fits using different distributions (exponential, Weibull, generalized gamma, log-logistic, log-normal) were performed. The Weibull and general gamma distributions were the two best fitting distributions according to the Akaike Information Criterion (AIC). The generalized gamma and Weibull distributions had very similar visual fit and long-term extrapolation with a mean time on treatment of 36.8 and 37.7 months, respectively. The generalized gamma probability distribution was deemed to be the most appropriate representation of discontinuation data and was, therefore, used in the base case. The same discontinuation rates were applied to both arms. After discontinuation, patients were assumed to experience the same SRE rates as patients who never received treatment to prevent SREs.

**Progression-free survival and overall survival rates**

PFS was defined as the time interval from the randomization date to the date of first overall disease progression assessed and recorded by the investigator, or death during treatment phase from any cause, whichever comes earlier. Data from study 20090482 showed an increasing separation between the denosumab and zoledronic acid PFS Kaplan–Meier curves from month 1 onwards\(^\text{20}\). Because the observed survival distributions for PFS were limited by the time of follow-up at primary analysis, it was necessary to extrapolate them beyond the currently available follow-up time to obtain unbiased estimates of the gains in life expectancy and QALYs in both treatment arms. This is a common approach to survival curves in modeling\(^\text{20}\). Extrapolation of PFS was performed by fitting parametric survival distributions to individual patient PFS data. The following exponential distributions were tested: exponential, Weibull, Gompertz, generalized gamma, log-logistic and log-normal. The three best fitting distributions in terms of AIC were the Weibull, the log-logistic and the generalized gamma distributions. The three distributions were all associated with similar AICs and with relatively good visual fit to the trial data. Generalized gamma probability distributions (Figure 2) were deemed to be appropriate representations of PFS for both arms because they provided a good visual and statistical fit of PFS data; the log-logistic distribution provided an implausible long-term extrapolation of PFS (PFS curves crossed the OS curve after around 250 model cycles, at which time more than 10% of patients were still alive) and the median difference in PFS estimated by the generalized gamma distribution was closer to the results of study 20090482 than that estimated by the Weibull distribution. Furthermore, use of the generalized gamma distribution is consistent with the treatment discontinuation distribution, under the assumption of a constant relationship between time-to-treatment-discontinuation and treatment effect (which was also made for the SRE rates). Moreover, generalized gamma distributions of PFS have been used elsewhere to model PFS in patients with MM\(^\text{40,41}\), and their projections appear to be clinically plausible. Rates were derived from the PFS probability distributions.

Mortality rates were derived from the OS probability distribution, extrapolated by fitting survival data from the two pooled arms of the trial. In the 20090482 study, OS was similar for denosumab and zoledronic acid and, therefore, the model assumed the same mortality rate for both
treatments. Parametric survival models with different probability distributions were fitted to the data (namely exponential, Weibull, generalized gamma, log-logistic and log-normal distributions) and were used to inform the model. A correction was made using the US national life tables to ensure mortality rates predicted by the model would always be higher or equal to the general population mortality. The Weibull distribution was selected in the base case as it was the best fitting distribution based on the AIC and provided good visual fit. Although the exponential, generalized gamma and log-logistic distribution had similar statistical goodness of fit, the long-term extrapolations were not plausible, with exponential and log-logistic distributions predicting implausibly high long-term survival, while the generalized gamma distribution crossed the PFS extrapolation before 10 years.

**Serious adverse event rates**

To reflect clinically and economically important events, SAEs reported in the 20090482 study were used to derive SAE rates in the model. Constant rates of SAEs were used. A SAE was defined as any untoward medical occurrence that resulted in death, was life-threatening, required prolonged hospitalization, or resulted in significant disability/incapacity and which did not necessarily have to have a causal relationship with the administered treatment. Three SAEs were used to derive SAE rates included in the base case—hypocalcemia, osteonecrosis of the jaw (ONJ) and renal toxicity. SAE rates were calculated in a manner similar to the calculation of SRE rates by using the total number of patients experiencing each SAE and dividing it by the person-time on study over which patients were followed for SAEs. SAE rates were based on the integrated summary of safety from the 20090482 study. The rates of SAEs of interest for denosumab and zoledronic acid were as follows: hypocalcemia (0.9% vs 0.2%); positively adjudicated ONJ (0.7% vs 0.2%); and SAEs related to renal toxicity (2.7% vs 3.5%).

**Model utilities**

Utility decrements were a consequence of SREs, SAEs (such as ONJ, hypocalcemia and renal toxicity), mode of drug administration (subcutaneous injections vs intravenous infusions) and MM disease progression (Table 4).

**Skeletal-related event utility decrements**

The SRE utility values were derived from a sample of participants from the general population who participated in a utility study, which was designed to establish the value that participants assigned to their quality of life, by hypothetically comparing varying life expectancies at different states of health. In this study, the utility decrements associated with the four types of SREs were assessed using eight health states—spinal cord compression (two health states: with and without paralysis), pathologic fracture (three health states: leg, rib and arm), radiation (two health states: administered in two appointments and administered daily for 2 weeks) and surgery performed to stabilize bone (one health state).

**Drug administration utility decrements**

A similar methodology was used for the assessment of the utility decrement associated with receiving a subcutaneous injection or intravenous infusion for SRE prevention (e.g. denosumab or zoledronic acid) in addition to antimyeloma chemotherapy. The utility decrement for one subcutaneous injection compared with no injection was 0.0011, and that for one intravenous infusion compared with no infusion was 0.0021.

**Serious adverse events utility decrements**

The SAE utility decrements were based on analyses performed using a regression model by pooling data across solid tumor trials (Table 4).
**Multiple myeloma progression utility decrements**

MM progression was modeled by applying a 19.5% decrement to the baseline utility of patients with non-progressive disease, as previously done by van Agthoven et al., 2004\(^{44}\), with a baseline utility of 0.80 for patients with non-progressive disease (typically such patients were on, or had recently completed, first-line antimyeloma treatment).

**Costs**

The model inputs included direct medical costs for drug acquisition, drug administration, SAEs, SRE management (hospital, outpatient, long-term care and hospice, strong opioid, ED visits, physical therapy and skilled nursing facility), direct non-medical costs (for caregiver time and driving/parking time to attend medical appointments) and indirect costs (short-term disability and productivity loss). All of the above costs were included in the societal perspective analysis. The payer perspective did not include direct non-medical costs and indirect costs.

Drug acquisition costs were based on average selling prices per dose (ASP; $1928 and $45 for denosumab and zoledronic acid, respectively) from the Centers for Medicare & Medicaid Services (Q3 2017)\(^{45}\). Wholesale drug acquisition costs per dose (WAC; $2155 and $922, respectively) in 2017 were used for an alternative scenario analysis (Table 5). The doses given were: denosumab 120 mg subcutaneously every 4 weeks, zoledronic acid 4 mg intravenously every 4 weeks. Modifications to the zoledronic acid dose were performed according to the label.

The costs of drug administration for subcutaneous injection and intravenous infusion (including an additional renal monitoring fee for each zoledronic acid administration) were taken from Stopeck et al., 2012\(^{28}\), and adjusted for inflation to 2017 prices. The costs of SAEs (such as ONJ, hypocalcemia and renal toxicity) were also included\(^{46,47}\) (Table 5). The monthly costs of antimyeloma treatments in first-, second- and third-line were based on WAC prices of regimens with at least 3% of market share (August 2017) weighted by their relative market shares and relative duration of use. The mean duration of each line of treatment was calculated as the mean duration of all the regimens with at least 3% of market share (August 2017) used for that line, weighted by their relative market shares.

The inpatient and outpatient costs associated with managing SREs, accounting for the proportion of patients admitted for inpatient hospitalization or treated in outpatient facilities, are summarized in Table 5.

The costs of SRE-related ED visits were calculated based on the study published by Nash et al., 2016\(^{31}\) evaluating the costs of treating patients with SREs versus treating those without SREs among patients with MM. Costs were reported as incremental cost per patient per month. Adjustments were made to account for the number of SREs during the follow-up period to estimate the cost per SRE. The SRE long-term care and hospice cost inputs were calculated based on a study by Jayasekara et al., 2014\(^{48}\) and long-term care based on an internal analysis of the MarketScan claims database (Amgen data on file, 2017). The SRE physical therapy and devices costs were based on an internal analysis of the MarketScan claims database. Also in this case, costs were reported as incremental cost per patient per month and adjustments were made for the number of SREs per year. Other SRE-related costs, associated with the use of skilled nursing facilities, strong opioid usage, caregiver burden and short-term disability and productivity loss were calculated based on multiple sources and are described in Table 5 (Amgen data on file, 2017)\(^{31,48-52}\). All values were adjusted for inflation by multiplying the cost by the Medical Care consumer price index of March 2017.

**Cost-effectiveness analysis**

The cost-effectiveness of denosumab was calculated primarily in terms of the ICER by dividing the difference in total cost (ΔC) between denosumab (C\(_{\text{denab}}\)) and zoledronic acid (C\(_{\text{zol}}\)) by the difference
in health outcomes (ΔE), measured in quality-adjusted life-years (QALYs) between denosumab (E_{dmab}) and zoledronic acid (E_{zol}), therefore: ICER = ΔC / ΔE. To help define the economic value of denosumab, we applied a threshold for health gains called the willingness to pay (WTP) threshold. This reflects the maximum amount that society is willing to pay for one additional QALY gained\(^\text{53}\). A constant 3% annual discount rate, to account for time preferences in health gains, was used in the model for both health and costs. For this analysis, the WTP threshold was assumed to be $150,000, which is consistent with the value previously used by several stakeholders in the USA, and with World Health Organization (WHO) recommendations\(^\text{53}\). The value of denosumab was also estimated by the NMB, calculated as NMB = [(E_{dmab} − E_{zol}) × WTP] − (C_{dmab} − C_{zol}). Cost-effectiveness and NMB analyses were conducted both from societal and payer perspectives. For the societal analysis, based on demographic considerations, 35% of patients were assumed to be eligible for short-term disability and productivity loss. This was based on the proportion of patients who would be assumed to be employed full time while being treated. After first-line antimyeloma treatment with a mean of nine cycles, patients who do not have disease progression incur significantly lower costs than those with progressive disease due to the initiation of a new antimyeloma treatment. To account for the uncertainties and complexities of the rapidly evolving MM treatment landscape, conservatively, only 50% of the potential savings associated with delaying initiation of second and subsequent lines of primary antimyeloma treatment were included in the calculations.

We also conducted three scenario analyses to understand how changes in various inputs impacted on the cost-effectiveness of denosumab versus zoledronic acid. First, we changed the drug acquisition cost to use the WAC rather than the ASP. This was conducted to reflect the fact that the price for zoledronic acid varies by region (and may be higher than the ASP in some institutions) and to assess how much value is lost when comparing an innovative and a generic product. Second, we changed the efficacy of denosumab compared with zoledronic acid for the prevention of SREs by incorporating results from the pre-specified 15-month post hoc analysis of the 20090482 study. In the primary analysis, used in the base case, most on-study SREs occurred within the first 3 months. Owing to the short duration of patient exposure to treatment this may not have been long enough to detect treatment differences. The 15-month post hoc analysis was conducted 1 year after most SRE events occurred, at a time point when the biological effect of each drug is likely to be measurable. Finally, we changed the proportion of patients with severe renal impairment from 10% to 25%. This was performed because real-world data suggest that the 10% used in the base case is probably a conservative estimate of the real-world proportion of patients with MM and severe renal impairment\(^\text{54}\).

The effect of parametric uncertainty on the ICER was evaluated via a one-way deterministic sensitivity analysis (this involved varying one parameter at a time to determine how model results were affected). The overall impact of the uncertainties affecting model parameters on the model output was evaluated using multivariate probabilistic sensitivity analyses (this involved varying multiple parameters simultaneously, the values of which were taken from their parameter-specific probability distributions, and then running the model 2000 times).

Results
Base case: societal and payer perspectives
From a societal perspective, based on the ASPs, the use of denosumab instead of zoledronic acid resulted in an incremental cost of $26,329 (about 5% of the total lifetime SRE-related and primary antimyeloma treatment costs; Table 6) and an incremental benefit measured by QALYs of 0.2439, which translated into a cost of $107,939 per QALY gained (Table 7) and an NMB difference of $10,259 in favor of denosumab (Table 7; Figure 3a). When based on the WAC prices, the same analysis resulted in an ICER of $34,895 per QALY gained.
From the payer perspective, based on the ASPs, the adoption of denosumab resulted in an incremental cost of $29,409 and an incremental benefit measured by a QALY of 0.2439, which translated into a cost of $120,569 per QALY gained and a NMB difference of $7179 in favor of denosumab (Table 8; Figure 3b). When based on the WAC prices, the same analysis resulted in an ICER of $47,525 per QALY gained.

With ICERs below the WTP threshold of $150,000/QALY, denosumab was found to be cost-effective versus zoledronic acid, both from a societal and payer perspective, and regardless of whether drug acquisition costs were based on the ASP or WAC.

**Additional scenarios: landmark analysis, patients with renal impairment and real-world adjustment factor**

When the results of the landmark analysis were considered, the ICER from the societal perspective was $74,514 per QALY. If the proportion of patients with severe renal impairment was increased to 25%, the ICER was $64,068 per QALY from a societal perspective. If the SRE rate was adjusted with a lower factor (2.1) and rates were based on the landmark analysis, the ICER was $102,585 per QALY from a societal perspective.

**Sensitivity analyses**

Univariate deterministic sensitivity analyses showed that the model results were relatively stable with respect to the values of key variables, and remained below the accepted threshold, with the exception of annual crude SRE rates and the post-progression utility decrement (see Figures 4 a and b).

Probabilistic multivariate sensitivity analyses showed that, at a WTP threshold of $150,000, the probability of denosumab being cost-effective versus zoledronic acid was more than 63% from the societal perspective and 60% from the payer perspective.

**Discussion**

To our knowledge, this is the first study to assess the cost-effectiveness of denosumab versus zoledronic acid in patients with MM. This analysis quantified the economic value delivered by denosumab to society and payers using the best available clinical and economic evidence to capture a wide range of costs and benefits accrued over a patient lifetime. The cost-effectiveness of denosumab compared with zoledronic acid in patients with MM holds for a WTP threshold of $150,000 per QALY gained, which is considerably lower than the $300,000 WTP threshold frequently used for cost-effectiveness analysis of novel drugs. Denosumab also delivered a positive NMB to both society and payers. By quantifying the comparative value of treatments, we hope that this analysis will support patients, clinicians and payers in making informed decisions on which agent to use for the prevention of SREs in patients with MM, which may ultimately help maximize patient outcomes. Given its substantial economic benefit, lack of renal toxicity, and expected impact on PFS, denosumab has the potential to provide value to patients, healthcare providers, payers and society.

Although previous studies have assessed the cost-effectiveness of denosumab compared with zoledronic acid in patients with solid tumors, it is not possible to directly compare the results of these previous analyses because of the different clinical settings. This is due to important differences in clinical outcomes reported from studies comparing the efficacy of these agents in solid tumors and in MM; denosumab has been shown to be superior compared with zoledronic acid in preventing SREs in patients with solid tumors, whereas in MM denosumab has been shown to be non-inferior in preventing SREs and to extend PFS compared with zoledronic acid.
This economic evaluation has a number of strengths. In particular, the majority of clinical inputs were generated within a large, well-designed, double blind, randomized, controlled study comparing denosumab with zoledronic acid in patients with newly diagnosed MM. The model also accounts for direct non-medical costs and indirect costs that are usually neglected in other analyses (which typically focus solely on direct medical costs), and provides a more holistic view of the value of innovative drugs, such as denosumab. Moreover, the model bridges the gap between randomized controlled trials and real-world practice by accounting for important comorbidities (i.e. renal impairment), the route of drug administration, the extrapolation of key clinical outcomes beyond the clinical study follow-up, the impact on MM treatment and the costs and burden for patients and caregivers.

There are, of course, several limitations and the results presented should be interpreted within the context of the data inputs and modeling assumptions adopted. For instance, the cost of SREs in patients with MM were assumed to be similar to the costs of SREs from solid tumors as cited in Stopeck et al., 2012. However, because these costs are associated specifically with treating SREs and not the primary tumor it is reasonable to assume that any cost differences between treating SREs in solid tumors and MM would be minor. Other costs of healthcare services were estimated from multiple published sources that were not necessarily derived from patients with MM and which varied by tumor type, patient population, country and other parameters. PFS, OS and time to discontinuation distributions were extrapolated beyond the follow-up of the primary analysis of the phase 3 study and it should be noted that long-term (lifetime) extrapolations are affected by uncertainty, as they depend on multiple factors (some of which are unknown) and on complex dynamics. Additionally, for simplicity, a medical consumer price index (CPI) for inflation was applied to all costs including non-medical costs. However, we anticipate that applying a non-medical CPI to non-medical costs would have minimal impact on the model. However, best modeling practices have been applied, and clinically and statistically motivated assumptions have been made whenever possible. Finally, sensitivity analyses have been used to test the robustness of the results.

**Conclusions**

This analysis shows that denosumab is a cost-effective option for the prevention of SREs in patients with MM compared with the current standard of care, zoledronic acid. This is due to its combined impact on reducing SREs and the observed improvement of PFS compared with zoledronic acid, as well as its lack of impact on renal function. The available evidence points to the conclusion that denosumab would remain cost-effective under a variety of scenarios, providing value to patients, payers and society.
References


55. Braithwaite RS, Meltzer DO, King JT, Jr., et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46:349–56


Tables and Figures

Table 1. SRE counts and distributions from the 20090482 study.

<table>
<thead>
<tr>
<th>SRE type</th>
<th>Number of SREs pooled arms (N = 1718)</th>
<th>SRE proportion (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathologic fractures</td>
<td>1280</td>
<td>81.6</td>
</tr>
<tr>
<td>Radiation to bone</td>
<td>174</td>
<td>11.1</td>
</tr>
<tr>
<td>Surgery to bone</td>
<td>104</td>
<td>6.6</td>
</tr>
<tr>
<td>Spinal cord compression</td>
<td>10</td>
<td>0.6</td>
</tr>
<tr>
<td>Overall</td>
<td>1568</td>
<td>100.0</td>
</tr>
</tbody>
</table>

SRE, skeletal-related event.
Source: Amgen data on file, 2017.

Table 2. SRE rates from the 20090482 study.

<table>
<thead>
<tr>
<th>Components of SRE rate calculation by treatment group</th>
<th>Multiple myeloma (study 482) full analysis set</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Denosumab (N = 859)</td>
</tr>
<tr>
<td>Number of SREs</td>
<td>764</td>
</tr>
<tr>
<td>Person-years of follow-up</td>
<td>1285.6</td>
</tr>
<tr>
<td>Rate per person-year</td>
<td>0.59</td>
</tr>
</tbody>
</table>

SRE, skeletal-related event.
A real-world adjustment factor of 2.84 was applied to both treatment arms.
Source: Amgen data on file, 2017.
**Table 3.** SRE rates from the 20090482 study (differential rates before and 15 months after the start of SRE preventive treatment).

<table>
<thead>
<tr>
<th></th>
<th>Denosumab 120 mg Q4W (N = 450)</th>
<th>Zoledronic acid 4 mg Q4W (N = 459)</th>
<th>Treatment difference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First 14 months</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of events</td>
<td>709</td>
<td>720</td>
<td></td>
</tr>
<tr>
<td>Mean number of events per subject</td>
<td>0.83</td>
<td>0.84</td>
<td>0.99 (0.87–1.13)</td>
</tr>
<tr>
<td>Rate ratio (95% CI)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p value</td>
<td></td>
<td></td>
<td>0.91</td>
</tr>
<tr>
<td><strong>Month 15 and after</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of events</td>
<td>55</td>
<td>84</td>
<td></td>
</tr>
<tr>
<td>Mean number of events per subject</td>
<td>0.12</td>
<td>0.18</td>
<td>0.71 (0.48, 1.05)</td>
</tr>
<tr>
<td>Rate ratio (95% CI)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p value</td>
<td></td>
<td></td>
<td>0.089</td>
</tr>
</tbody>
</table>

CI, confidence interval; SRE, skeletal-related event.

Source: Amgen data on file, 2017.
### Table 4. Utility decrements.

<table>
<thead>
<tr>
<th>SRE type</th>
<th>Utility decrement</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathologic fracture</td>
<td>0.100</td>
<td>Matza et al., 2014&lt;sup&gt;43&lt;/sup&gt;</td>
</tr>
<tr>
<td>Radiation to bone</td>
<td>0.120</td>
<td>Matza et al., 2014&lt;sup&gt;43&lt;/sup&gt;</td>
</tr>
<tr>
<td>Surgery to bone</td>
<td>0.160</td>
<td>Matza et al., 2014&lt;sup&gt;43&lt;/sup&gt;</td>
</tr>
<tr>
<td>Spinal cord compression</td>
<td>0.500</td>
<td>Matza et al., 2014&lt;sup&gt;43&lt;/sup&gt;</td>
</tr>
<tr>
<td>Serious AE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ONJ</td>
<td>0.010</td>
<td>Stopec et al., 2012&lt;sup&gt;28&lt;/sup&gt;</td>
</tr>
<tr>
<td>Hypocalcemia</td>
<td>0.008</td>
<td>Stopec et al., 2012&lt;sup&gt;28&lt;/sup&gt;</td>
</tr>
<tr>
<td>Renal toxicity</td>
<td>0.015</td>
<td>Stopec et al., 2012&lt;sup&gt;28&lt;/sup&gt;</td>
</tr>
<tr>
<td>Mode of administration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SC injection</td>
<td>0.0011</td>
<td>Amgen data on file, 2017</td>
</tr>
<tr>
<td>IV infusion</td>
<td>0.0021</td>
<td>Amgen data on file, 2017</td>
</tr>
<tr>
<td>MM disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-progressed</td>
<td>0.800</td>
<td>van Agthoven et al., 2004&lt;sup&gt;44&lt;/sup&gt;</td>
</tr>
<tr>
<td>Progressed</td>
<td>0.644</td>
<td>van Agthoven et al., 2004&lt;sup&gt;44&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

AE, adverse event; IV, intravenous; MM, multiple myeloma; ONJ, osteonecrosis of the jaw; SC, subcutaneous injection; SRE, skeletal-related event.

### Table 5. Summary of all cost inputs.
<table>
<thead>
<tr>
<th>Direct costs (2017 adjusted costs)</th>
<th>Cost (US$)</th>
<th>Unit</th>
<th>Source for cost calculations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Drug costs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug cost – denosumab</td>
<td>1928/2155</td>
<td>Per dose</td>
<td>ASP/WAC</td>
</tr>
<tr>
<td>Drug cost – zoledronic acid</td>
<td>45/922</td>
<td>Per dose</td>
<td>ASP/WAC</td>
</tr>
<tr>
<td><strong>Administration costs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administration fee – denosumab</td>
<td>42.18</td>
<td>Per dose</td>
<td>Stopec et al., 2012</td>
</tr>
<tr>
<td>Administration fee – zoledronic acid</td>
<td>184.17</td>
<td>Per dose</td>
<td>Stopec et al., 2012</td>
</tr>
<tr>
<td>Renal monitoring fee</td>
<td>25.52</td>
<td>Per dose</td>
<td>Stopec et al., 2012</td>
</tr>
<tr>
<td><strong>Costs by SRE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inpatient</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vertebral or non-vertebral fracture</td>
<td>9146</td>
<td>Per SRE episode</td>
<td>Barlev et al., 2010</td>
</tr>
<tr>
<td>Radiation to bone</td>
<td>2228</td>
<td>Per SRE episode</td>
<td>Barlev et al., 2010</td>
</tr>
<tr>
<td>Surgery to bone</td>
<td>38,557</td>
<td>Per SRE episode</td>
<td>Barlev et al., 2010</td>
</tr>
<tr>
<td>Spinal cord compression</td>
<td>27,466</td>
<td>Per SRE episode</td>
<td>Barlev et al., 2010</td>
</tr>
<tr>
<td>Outpatient</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vertebral or non-vertebral fracture</td>
<td>1713</td>
<td>Per SRE episode</td>
<td>Stopec et al., 2012</td>
</tr>
<tr>
<td>Radiation to bone</td>
<td>10,003</td>
<td>Per SRE episode</td>
<td>Stopec et al., 2012</td>
</tr>
<tr>
<td>Surgery to bone</td>
<td>523</td>
<td>Per SRE episode</td>
<td>Stopec et al., 2012</td>
</tr>
<tr>
<td>Spinal cord compression</td>
<td>1611</td>
<td>Per SRE episode</td>
<td>Stopec et al., 2012</td>
</tr>
<tr>
<td>Emergency department</td>
<td>536</td>
<td>Per SRE episode</td>
<td>Nash Smyth et al., 2016</td>
</tr>
<tr>
<td>Long-term care and hospice</td>
<td>85</td>
<td>Per SRE episode</td>
<td>LTC: Amgen MarketScan DoF Hospice (Amgen data on file, 2017), Jayasekera et al., 2014</td>
</tr>
<tr>
<td>Physical therapy and devices</td>
<td>11</td>
<td>Per SRE episode</td>
<td>Amgen MarketScan DoF (Amgen data on file, 2017)</td>
</tr>
<tr>
<td>Skilled nursing facility</td>
<td>1744</td>
<td>Per SRE episode</td>
<td>Calculated on Jayasekera et al., 2014</td>
</tr>
<tr>
<td>Strong opioid use</td>
<td>26</td>
<td>Per SRE episode</td>
<td>Calculated on von Moos et al., 2016</td>
</tr>
<tr>
<td>SAEs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ONJ</td>
<td>660</td>
<td>Per SAE episode</td>
<td>Xie et al., 2011, Bell et al., 2011</td>
</tr>
<tr>
<td>Hypocalcemia</td>
<td>166</td>
<td>Per SAE episode</td>
<td>Xie et al., 2011, Bell et al., 2011</td>
</tr>
<tr>
<td>Renal toxicity</td>
<td>292</td>
<td>Per SAE episode</td>
<td>Xie 2011, Bell 2011</td>
</tr>
<tr>
<td>MM treatment costs (per month)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First line</td>
<td>18,272</td>
<td>Per month</td>
<td>Based on WAC prices as of September 6, 2017</td>
</tr>
<tr>
<td>Second line</td>
<td>18,256</td>
<td>Per month</td>
<td>Based on WAC prices</td>
</tr>
</tbody>
</table>
Third line 18,367 Per month as of September 6, 2017
Based on WAC prices as of September 6, 2017

Direct non-medical and indirect costs (2017 adjusted costs)
SRE visit driving and parking time 58 Per SRE episode 2 hours driving for bone complication visit with a $5 parking fee. Average hourly rates used at a cost of $26.49 (BLS)

SRE caregiver burden 4835 Per SRE episode Gridelli et al., 2007
Short-term disability and productivity loss 894 Per SRE episode Qian et al., 2015

ASP, average selling price; BLS, United States Bureau of Labor Statistics; MM, multiple myeloma; ONJ, osteonecrosis of the jaw; SAE, serious adverse event; WAC, wholesale drug acquisition costs.

Table 6. Costs by category (discounted).

Table 7. Comparator incremental cost-effectiveness ratio results from the societal perspective.

MM, multiple myeloma; SAE, serious adverse event; SRE, skeletal-related event.

ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
Table 8. Comparator incremental cost-effectiveness ratio results from the payer perspective.

<table>
<thead>
<tr>
<th>Results (discounted)</th>
<th>Denosumab</th>
<th>Zoledronic acid/no treatment</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Costs, US$</td>
<td>451,320</td>
<td>421,911</td>
<td>29,409</td>
</tr>
<tr>
<td>QALYs</td>
<td>3.400</td>
<td>3.156</td>
<td>0.2439</td>
</tr>
<tr>
<td>Cost per QALY (ICER), US$</td>
<td></td>
<td>120,569</td>
<td></td>
</tr>
<tr>
<td>Net monetary benefit, US$</td>
<td></td>
<td>7179</td>
<td></td>
</tr>
</tbody>
</table>

ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
Figure 1. Depiction of model health states.

1L, first line; 2L+, second line or later; MM, multiple myeloma; OFF SRE Prev Tx, patients not receiving treatment to prevent SREs; ON SRE Prev Tx, patients receiving treatment to prevent SREs; SRE, skeletal-related event; Tx, treatment.

Figure 2. Progression-free survival parametric model (unrestricted generalized gamma distributions compared with Kaplan–Meier curves).

KM, Kaplan–Meier; MM, multiple myeloma; PFS, progression-free survival.

Figure 3. Net monetary benefit of denosumab versus zoledronic acid in patients with multiple myeloma from (a) the societal perspective and (b) the payer perspective.

Societal perspective included SRE direct costs (hospital, outpatient, long-term care and hospice, strong opioid, emergency department visits, physical therapy and skilled nursing facility), QALY monetization and direct non-medical (driving and parking, caregiver) and indirect costs (short-term disability and productivity loss). Payer perspective included SRE direct costs (hospital, outpatient, long-term care and hospice, strong opioid, emergency department visits, physical therapy and skilled nursing facility) and QALY monetization. Assumed 50% MM treatment cost offsets and 35% patients eligible for short-term disability and productivity loss. Drug acquisition costs were based on average sales prices.

MM, multiple myeloma; NMB, net monetary benefit; QALY, quality-adjusted life year; SAE, serious adverse event; SRE, skeletal-related event; ZA, zoledronic acid.

Figure 4. One-way deterministic sensitivity analyses of key variables from (a) the societal perspective (b) the payer perspective.

Ranges for parameters used were as follows: annual efficacy discount rate, 0.00–0.05; percentage of patients not eligible to receive zoledronic acid, 0.05–0.15; annual crude SRE rate denosumab, 0.55–0.64; annual crude SRE rate zoledronic acid, 0.58–0.67; real world adjustment SRE rate, 2.01–4.01; SRE rate ratio for zoledronic acid versus no treatment, 0.42–0.82; zoledronic acid cost of administration, 189–231; denosumab number of cycles, 0.79–0.97; zoledronic acid number of cycles, 0.77–0.94; post-progression utility decrement, 0.57–0.72; QALY decrement SC, 0.0009–0.0014; QALY decrement IV, 0.0017–0.0025; QALY decrement vertebral fracture, 0.05–0.15; QALY decrement non-vertebral fracture, 0.05–0.15; MM second-line treatment duration, 7.66–9.36; percentage of potential savings in anti-MM treatment used in the cost-effectiveness analysis, 0.40–0.60; second-line MM treatment monthly costs, 16,430–20,081; third-line MM treatment monthly costs, 16,530–20,204.

2L, second line; 3L, third line; CE, cost-effectiveness analysis; IV, intravenous; MM, multiple myeloma; RR, risk ratio; SC, subcutaneous injection; SRE, skeletal-related event; QALY, quality-adjusted life-year.